Pancreatic disease is the fourth driving reason for malignancy related passing. The trouble in identifying pancreatic malignant growth at a beginning period, forcefulness and the absence of powerful treatment all add to the high mortality. Epidermal development factor receptor (EGFR) is a trans membrane glycoprotein, which is communicated in ordinary human tissues. It is an individual from the tyrosine kinase group of development factors receptors and is encoded by proto-oncogenes. A few investigations have shown that EGFR is over-communicated in pancreatic malignant growth. Over-articulation connects with further developed infection, poor endurance and the nearness of metastases. Subsequently, restraint of the EGFR flagging pathway is an alluring remedial objective. Albeit a few mixes of EGFR inhibitors with chemotherapy exhibit hindrance of tumor-initiated angiogenesis, tumor cell apoptosis and relapse in xenograft models, these advantages stay to be affirmed. Multimodality treatment joining EGFR-hindrance is developing as a novel system in the treatment of pancreatic malignancy.